Cancer Immunotherapy Toxicity Evaluation (CITE) Program
Cancer
On this page
Why choose UCSF Health for epilepsy? test
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
Why choose UCSF Health for epilepsy? test
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
Icon grid component
Headline here
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed sed mi metus.Icon GridOpens in a new window
Phasellus in felis sit amet augue pulvinar accumsan vel a purus.Service page Icon Grid Card 3
This card has no link added!Lorem ipsum dolorOpens in a new window
Cras gravida orci vel ex efficitur, nec mattis erat efficitur. Phasellus in felis sit amet augue pulvinar accumsan vel a purus.
UCSF Health is here for all your healthcare needs
Connect with a team that can help you find resources, solve problems, and advocate for you during treatment at UCSF.
Longer title here lorem ipsum dolor
Fusce quis tincidunt lorem, ut blandit neque.Icon Grid Card 2 in QA folderOpens in a new window
Phasellus aliquam pretium malesuada. Sed at gravida risus. Pellentesque sem magna, rhoncus ut ex id, tincidunt malesuada mi.No link here!
Short description!Dolor sit amet
Augue etiam scelerisque magna pellentesque diam auctor magna rhoncus.
UCSF Cancer Immunotherapy Toxicity Evaluation (CITE) Program
Immunotherapy harnesses the patient's own immune system to help fight their cancer. These cutting-edge treatments – which include cancer vaccines, cellular therapies, immune checkpoint inhibitors and other drugs – can sometimes overstimulate the immune system, leading to side effects that range from minor to serious.
Some side effects are easily managed with steroids, while others require care from experts in specific organ systems or immunosuppression (techniques to curb the immune response). Sometimes these side effects necessitate suspending the patient's cancer treatment, and there may be questions about whether it's safe to restart.
The UCSF Cancer Immunotherapy Toxicity Evaluation (CITE) Program
cares for patients with complex, difficult-to-treat side effects from immunotherapy. If you're experiencing such side effects, you may be finding it challenging to get a correct diagnosis and access to appropriate providers. The CITE Program brings together a dedicated, experienced team of oncologists and other specialists – including endocrinologists, gastroenterologists, neurologists, dermatologists and others – who will collaboratively manage your condition.
Our care team also serves as a resource for doctors outside UCSF seeking second opinions on their patients with immunotherapy-related side effects. The CITE Program is one of a kind in the Bay Area and among the first of its kind in the nation. In addition to patient care, our team is dedicated to advancing research on immunotherapy through clinical trials (studies of promising new treatments) and the banking of blood and tissue specimens. Our program works closely with other specialty groups at UCSF, including the Cancer Immunotherapy Program, which evaluates these agents in early phases of development.
Learn more about clinical trials and how they work.
Research
Clinical trials
ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin LymphomaOpens in a new window
Recruiting
To determine the ctDNA/MRD negative, PET negative complete response rate for cHL, participants undergoing treatment with pembro + GVD will have a composite res...Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged LeukemiaOpens in a new window
Recruiting
For the safety phase, DLTs of the induction + venetoclax cycle of KMT2A-rearranged (R) patients will be assessed.Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell LymphomaOpens in a new window
Recruiting
Time from first study treatment to first occurrence of progression (as assessed by the Independent Review Committee) or death, whichever occurs first
Media Feature
Media Feature: approach
Connect with a team that can hep you find resources, solve problems and advocate for you during treatment.
Related Content Grid CE Headline field
Related Providers 2
Zara Szeftel, MD
Psychiatry (Child and Adolescent Psychiatry) • Psychiatry
Christopher E. Freise, MD
Transplant Surgery (Pancreas) • Transplant Surgery
Huie Lin, MD
Cardiology (Interventional Cardiology) • Cardiology (Adult Congenital Heart Disease)
Peter G. Stock, MD, PhD
Transplant Surgery • Pediatric Transplant Surgery
Conditions & treatments
Services
- Cancer Physical Therapy
- Cancer Prevention
- Radiology (Abdominal Imaging)
- Abdominal Transplant Surgery
- Aesthetic and Cosmetic Ophthalmic Surgery
- Pediatric Acupuncture
- Addiction Counseling
- Adult Congenital Cardiac Disease
- Psychiatry (Child and Adolescent Psychiatry)
Conditions
- Lymphoma
- Arnold-Chiari Malformation Type 2
- Checkpoint Kinase 2
- Neurofibromatosis Type 1
Treatments
- 2-Stage Revision of Hip Replacement
- 3D Conformal Radiation Therapy
- 2-Stage Revision of Knee Replacement
- I-131 Ablation for Hyperthyroidism
- Open Abdominal Aortic Aneurysm Repair
- Abdominal Aneurysm Repair
- Abdominal Aorta Aneurysm Repair
- Hemoglobin A1c Blood Test
- Removal of Infected Abdominal Graft